Related references
Note: Only part of the references are listed.CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al.
BLOOD (2014)
Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies
Zhi Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity
Sylvia Herter et al.
JOURNAL OF IMMUNOLOGY (2014)
Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions
Christian Kellner et al.
METHODS (2014)
Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity
Sang Taek Jung et al.
ACS CHEMICAL BIOLOGY (2013)
Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Eric O. Long et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
Jacob M. Rowe et al.
BLOOD (2013)
Classification of human natural killer cells based on migration behavior and cytotoxic response
Bruno Vanherberghen et al.
BLOOD (2013)
NK cell-based immunotherapy for malignant diseases
Min Cheng et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
Andrew J. Cowan et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2013)
Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells
Paul J. Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Roland B. Walter et al.
BLOOD (2012)
Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in MLL-Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands
Wing Keung Chan et al.
CLINICAL CANCER RESEARCH (2012)
Single-cell analysis of the dynamics and functional outcomes of interactions between human natural killer cells and target cells
Yvonne J. Yamanaka et al.
INTEGRATIVE BIOLOGY (2012)
Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity
Jennifer T. Grier et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors
Jing Ni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Cutting Edge: Tumor-Targeting Antibodies Enhance NKG2D-Mediated NK Cell Cytotoxicity by Stabilizing NK Cell-Tumor Cell Interactions
Jacques Deguine et al.
JOURNAL OF IMMUNOLOGY (2012)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman et al.
PLOS ONE (2012)
Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
Suresh Veeramani et al.
BLOOD (2011)
Molecular Mechanisms of Natural Killer Cell Activation
Yenan T. Bryceson et al.
JOURNAL OF INNATE IMMUNITY (2011)
HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity
Gregor F. Lichtfuss et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
NK cell development, homeostasis and function: parallels with CD8+ T cells
Joseph C. Sun et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
Holly M. Horton et al.
BLOOD (2010)
In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
Simone de Haij et al.
CANCER RESEARCH (2010)
Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells
Sang Taek Jung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors
Yenan T. Bryceson et al.
BLOOD (2009)
The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates
Jonathan Zalevsky et al.
BLOOD (2009)
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia
May Kung Sutherland et al.
MABS (2009)
Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving
Paul V. Beum et al.
JOURNAL OF IMMUNOLOGY (2008)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificity
Y Mazor et al.
MOLECULAR IMMUNOLOGY (2005)
Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity
C Dunn et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
